Drug intelligence / Profile preview

BI 765883

Development stage: Discontinued
Lead developer: Boehringer Ingelheim
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

BI 765883 is an investigational antineoplastic drug candidate developed by Boehringer Ingelheim. It is a new molecular entity currently in Phase I clinical trials for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), including patients who have relapsed within six months after post-surgery adjuvant therapy. The drug is administered intravenously and is being evaluated both as monotherapy and in combination with chemotherapy agents such as gemcitabine and nab-paclitaxel. As of now, the precise mechanism of action for BI 765883 has not been disclosed[1][3][5][7].

Beyond the preview

Go deeper on BI 765883.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 765883.

Explore the full profile